Any Solid Tumor

Alisertib (MLN8237)

Description:

Alisertib is orally available small molecule inhibitor of Aurora A kinase that plays important role in cell mitosis. This Phase I study evaluates the effect of food on the pharmacokinetics of Alisertib in patients with advanced solid tumors or lymphomas.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Category: Solid Tumors/Non-Hematological
Contact: Epp Goodwin at (210) 450-5798

AV-203

Description:

AV-203 is a monoclonal antibody that selectively targets the receptor ERBB3 and inhibits its activity. This receptor is expressed in many human cancers and is associated with cancer growth and survival and in development of resistance to anti-cancer agents. In this Phase I study AV-203 is administered intravenously once every 2 weeks in patients with metastatic or advanced solid tumors.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

BAX69

Description:

BAX69 is an anti-macrophage migration inhibitory factor (anti-MIF) antibody. MIF is a pro-inflammatory cytokine that is up-regulated in many human cancers and contributes to growth, angiogenesis and migration of cancer cells. BAX69 is administered intravenously every 2 weeks in a 28 day cycle in patients with malignant solid tumors.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

BGJ398+BYL719

Description:

BGJ398 is an orally bioavailable inhibitor of human fibroblast growth factor receptor (FGFRs) with potential antiangiogenic and antineoplastic activities. BYL719 is an oral selective PI3K a isoform inhibitor. In this Phase I study BGJ398 in combination with BYL719 is administered in patients with select solid tumors that have PIK3CA gene mutation with or without FGFR genetic alteration.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

CBL0137

Description:

CBL0137 is a small molecule in the carbazole family affecting p53 and NF-kappa B signal transduction pathways. It is administered intravenously on days 1, 8 and 15 every 28 days in patients with metastatic or advanced solid tumors and refractory lymphomas.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Category: Solid Tumors/Non-Hematological
Contact: Epp Goodwin at (210) 450-5798

GSK2118436

Description:

GSK2118436 is an orally bioavailbale inhibitor of B-raf protein which may inhibit the proliferation of tumor cells with mutated BRAF gene. It is administered in patients with V600 BRAF mutation positive tumors. Previous exposure to BRAF inhibitors is allowed.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

IMGN853

Description:

IMGN853 is an immunoconjugate consisting of the humanized monoclonal antibody against folate receptor 1 (FOLR1) conjugated to the cytotoxic maytansinoid DM4. It is administered once every 21 days intravenously in patients with advanced solid tumors with FOLR1 expression. Tumor types which have a high incidence of FOLR1 positivity (serous or endometroid epithelial ovarian cancer, serous endometrial cancer, NSCLC of adenocarcinoma and bronchoalveolar cancer and clear cell renal carcinoma) can enroll without the specific testing.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

LDE225

Description:

LDE225 is an oral selective Smo antagonist that downregulates the Hedgehog signal transduction pathway. In this Phase I study the patients with advanced solid tumors receive LDE225 with Warfarin or Bupropion to evaluate the drug-drug interaction.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

RO5429083

Description:

RO5429083 is a humanized monoclonal antibody that binds to CD44, a transmembrane glycoprotein that is expressed in many cells, but what seems to have a more critical role in malignant growth. It is given as an IV infusion once every 2 weeks in patients with metastatic and/or advanced solid tumors that express CD44.


Type(s) of Cancer: Any Solid Tumor
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798